Untech
Untech is a drug development company dedicated to treating chronic wounds. They have developed a groundbreaking gel that addresses the three key stages of drug development: biotechnology, pre-clinical studies, and clinical studies. Their mission is to help the 120 million people worldwide suffering from chronic wounds by providing an effective healing solution. The team is composed of scientists and entrepreneurs with extensive experience in biotechnology and pharmaceutical industries, working to improve patient outcomes and bring definitive solutions to chronic health problems.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Topical therapeutic gel for chronic wounds
A topical gel formulation combining molecules and enzymes, designed to disrupt biofilm, exert antimicrobial effects, provide local anesthesia and promote biological processes associated with wound healing.
First-in-class topical hydrogel
A topical hydrogel designed to move chronic wounds from chronicity to regeneration by reducing pain, inflammation, and amputation risk, delivering direct topical therapy that fights infections and regenerates skin.
Untech Therapeutic Gel
A gel developed to cover three main therapeutic requirements for chronic wound healing: anti-pathogenic, anesthetic, and pro-healing effects. It disrupts biofilm-forming bacteria, inhibits MMPs and free radicals, promotes wound oxygenation and collagenization, and allows patient self-application.
Topical therapeutic gel for chronic wounds
A topical gel formulation combining molecules and enzymes, designed to disrupt biofilm, exert antimicrobial effects, provide local anesthesia and promote biological processes associated with wound healing.
First-in-class topical hydrogel
A topical hydrogel designed to move chronic wounds from chronicity to regeneration by reducing pain, inflammation, and amputation risk, delivering direct topical therapy that fights infections and regenerates skin.
Untech Therapeutic Gel
A gel developed to cover three main therapeutic requirements for chronic wound healing: anti-pathogenic, anesthetic, and pro-healing effects. It disrupts biofilm-forming bacteria, inhibits MMPs and free radicals, promotes wound oxygenation and collagenization, and allows patient self-application.
Services
Design and execution of animal studies to evaluate safety and efficacy of topical wound therapies prior to human trials.
Execution of early-stage clinical studies to assess safety and therapeutic effectivity in patients with chronic wounds.
Design and execution of animal studies to evaluate safety and efficacy of topical wound therapies prior to human trials.
Execution of early-stage clinical studies to assess safety and therapeutic effectivity in patients with chronic wounds.
Expertise Areas
- Chronic wound therapeutics
- Topical formulation development
- Antimicrobial and anti-biofilm therapeutics
- Preclinical in vivo studies (wound models)
Key Technologies
- Topical hydrogel formulations
- Biofilm-disruption methods
- Antimicrobial susceptibility and biofilm assays
- Matrix metalloproteinase (MMP) modulation
News & Updates
Our offices
112 Capitol Trail, Newark, Delaware 19711, United States; Av. Perón 2000, 2nd – Of 10B, Complejo Altercity – 3rd Building, Yerba Buena, Tucumán 4107, Argentina.
Untech's Mission and Solution
Untech focuses on chronic wound treatment, having developed a gel that works as an anti-pathogenic, anesthetic, and pro-healing agent. They have conducted extensive research and clinical studies, achieving a 100% success rate in exploratory clinical studies.
Awards and Recognition
Untech has received numerous awards including first prizes at various scientific congresses and entrepreneurship contests, as well as recognition from institutions like Singularity University, MIT, and Stanford University.
Awarded in 2014 for their work in ulcers and wounds.
Awarded in 2013 for their contributions to pharmaceutical sciences.
Our offices
112 Capitol Trail, Newark, Delaware 19711, United States; Av. Perón 2000, 2nd – Of 10B, Complejo Altercity – 3rd Building, Yerba Buena, Tucumán 4107, Argentina.
Untech's Mission and Solution
Untech focuses on chronic wound treatment, having developed a gel that works as an anti-pathogenic, anesthetic, and pro-healing agent. They have conducted extensive research and clinical studies, achieving a 100% success rate in exploratory clinical studies.
Awards and Recognition
Untech has received numerous awards including first prizes at various scientific congresses and entrepreneurship contests, as well as recognition from institutions like Singularity University, MIT, and Stanford University.
Awarded in 2014 for their work in ulcers and wounds.
Awarded in 2013 for their contributions to pharmaceutical sciences.